Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
So, Cytokinetics will receive an Upfront Payment of 50 million from Bayer. And Cytokinetics can potentially get an additional 90 million through various milestones leading up to the commercial launch, including 20 million in the near term. Also, there is potential for up to 490 million in commercial milestone payments based on the achievement of certain sales targets. As the result, Cytokinetics will receive additional revenue stream through tiered royalties on the sales of Aficamten in Japan. Warning! GuruFocus has detected 8 Warning Signs with CYTK. For information, milestone here refers to a business segment of Cytokinetics that make up to 46.5% of total revenue. This is substantial for Cytokinetics remember that its 2023 revenue was $7.53 million only. Bayer is now going to conduct Phase 3 clinical trials for obstructive HCM in Japan, while Cytokinetics will expand its ongoing ACACIA-HCM and CEDAR-HCM trials into Japan. With Bayer's extensive experience in cardiovascula
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
- Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyGlobeNewswire
- Why Cytokinetics Stock Was a Nearly 5% Winner Today [Yahoo! Finance]Yahoo! Finance
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.MarketBeat
CYTK
Earnings
- 11/6/24 - Miss
CYTK
Sec Filings
- 12/16/24 - Form 4
- 12/16/24 - Form 8-K
- 12/16/24 - Form 144
- CYTK's page on the SEC website